Literature DB >> 10869751

Pelvic fractures following irradiation of endometrial and vaginal cancers-a case series and review of literature.

P Tai1, A Hammond, J V Dyk, L Stitt, J Tonita, T Coad, J Radwan.   

Abstract

PURPOSE: To review the induction of pelvic fractures as a result of radiation therapy and to assess their management.
MATERIALS AND METHODS: The charts of patients with endometrial and vaginal cancers irradiated between 1991 and 1995 were reviewed. All patients were treated with megavoltage machines, energy ranging from cobalt to 25 MV photons.
RESULTS: We treated 336 patients, with a median follow-up duration of 28.9 months (range 0-73.3). Sixteen patients had symptomatic pelvic fractures. The 5-year actuarial incidence of symptomatic pelvic fracture was 2.1%. All patients had pain as the first symptom. The median time of onset was 11 months (range 4-46). Imaging studies of 37.5% (6/16) were initially interpreted to be recurrent malignancy. All patients were managed conservatively and nine patients showed radiological evidence of healing over a median time of 13 months (range 2-34). Six patients had specific drug treatment including provera, premarin, calcium supplements, or pamidronate. Of these, five healed. For the ten patients who did not have any specific treatment, only four showed signs of healing at the time of last follow-up. There was a trend toward earlier healing with specific drug treatment (P=0.11).
CONCLUSIONS: Fractures can easily be mistaken for metastatic lesions (37.5% in this series) which might be treated with further irradiation. Although not statistically significant, there was a trend towards early healing with drug therapy. More studies are required to generate quantitative data for dose-response relationships and to evaluate the effect of drug therapy on the healing of such fractures.

Entities:  

Mesh:

Year:  2000        PMID: 10869751     DOI: 10.1016/s0167-8140(00)00178-x

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  7 in total

1.  Low backache in a 70-year-old woman.

Authors:  Aditya V Maheshwari; Jeremy S Frank; J David Pitcher; H Thomas Temple
Journal:  Clin Orthop Relat Res       Date:  2008-02-14       Impact factor: 4.176

2.  Pelvic imaging following chemotherapy and radiation therapy for gynecologic malignancies.

Authors:  Helen C Addley; Hebert Alberto Vargas; Penelope L Moyle; Robin Crawford; Evis Sala
Journal:  Radiographics       Date:  2010-11       Impact factor: 5.333

Review 3.  Pelvic insufficiency fracture (PIF) incidence in patients treated with intensity-modulated radiation therapy (IMRT) for gynaecological or anal cancer: single-institution experience and review of the literature.

Authors:  Louis Bazire; Haoping Xu; Jean-Philippe Foy; Malika Amessis; Caroline Malhaire; Kim Cao; Anne De La Rochefordiere; Youlia M Kirova
Journal:  Br J Radiol       Date:  2017-03-14       Impact factor: 3.039

4.  From radiation osteitis to osteoradionecrosis: incidence and MR morphology of radiation-induced sacral pathologies following pelvic radiotherapy.

Authors:  Adrian J Meixel; Henrik Hauswald; Stefan Delorme; Björn Jobke
Journal:  Eur Radiol       Date:  2018-02-23       Impact factor: 5.315

5.  Osteoradionecrosis of the Hip, a Troublesome Complication of Radiation Therapy: Case Series and Systematic Review.

Authors:  Sheng-Hao Xu; Jin-Shuo Tang; Xian-Yue Shen; Zhi-Xin Niu; Jian-Lin Xiao
Journal:  Front Med (Lausanne)       Date:  2022-03-25

6.  Pelvic insufficiency fracture after radiotherapy in patients with cervical cancer in the era of PET/CT.

Authors:  Shin-Hyung Park; Jae-Chul Kim; Jeong-Eun Lee; In-Kyu Park
Journal:  Radiat Oncol J       Date:  2011-12-28

7.  Pelvic insufficiency fracture after definitive radiotherapy for uterine cervical cancer: retrospective analysis of risk factors.

Authors:  Haruka Uezono; Kayoko Tsujino; Keno Moriki; Fumiko Nagano; Yosuke Ota; Ryohei Sasaki; Toshinori Soejima
Journal:  J Radiat Res       Date:  2013-05-17       Impact factor: 2.724

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.